In-Vitro Toxicology Testing Market is Expected to Reach USD 44.7 Billion by 2022

The global in-vitro toxicology testing market is expected to reach USD 44.7 billion by 2022 growing at an estimated CAGR of 10.5% from 2015 to 2022, according to a new report by Grand View Research, Inc. This expected rise in demand can be ascribed to novel and promising technologies in analytical laboratories. 

Advancement in bioinformatics based research for development of efficient software algorithms in order to carry out efficient stimulation of in-silico animal models in determination of toxicological response is expected to influence sector growth through to 2022. 

Furthermore, rapid up gradation of databases that serve information for toxicity profiling and lethal dose determination of different compounds is anticipated to create significant potential for growth in this market during the forecast period. 

Rise in government imposed restrictions and guidelines on usage of animals for pre-clinical research and toxicology testing is also attributive towards estimated progress in this industry.

Additionally, increasing R&D in biotechnology sector for enhancement in cell based assays and cell culture techniques, is anticipated to impart significant growth potential in this sector. 

North America In-vitro Toxicology Testing Market, By Technology 2012-2022 (USD Million)

View summary of "In-vitro Toxicology Testing Market Analysis Report"  

Further key findings from the study suggest:

• Pharmaceutical and cosmetic industry together accounted for almost 65% of total revenue generated in this sector for 2014. This large share can be attributed to rapid novel product launches for treatment of different diseased conditions wherein toxicological testing is the pre-requisite step. 

• Cell culture technology contributed for over 42% of the revenue generated in the industry with respect to technology owing to critical role of cell culture in biotechnological development and cell based analysis 

• Omics technology is anticipated to register lucrative growth thereby driving demand due to advancement in sequencing methods and availability of different platforms depending on source and target sequence. 

• As a fundamental process in biopharmaceutical or pharmaceutical product development toxicological testing finds application in determination of systemic, dermal, & ocular toxicity as well as endocrine disruption 

• Amongst the above enlisted applications, dermal toxicity is expected to witness significant progress with a CAGR of approximately 13% due to comparatively higher incidence of side effects associated with skin after administration of several compounds. 

• North America accounted for the largest share of over 45% in revenue in 2014 owing to presence of significant number of sector players that are implementing advanced in-vitro technology. Furthermore, presence of stringent regulations pertaining to animal usage in toxicity analysis attributive towards high demand of in-vitro tests in this region. 

• Asia Pacific is expected to witness lucrative CAGR of over 11% from 2015 to 2022 due to rapid improvement in health care infrastructure in developing economies of this region which in turn contributes to regional progress in industry. 

• Key participants of in-vitro toxicology testing industry are Quest Diagnostics, Covance, Cyprotex, Alere, Inc, Charles River Laboratories, GE Healthcare, Thermo Fisher Scientific, Eurofins Scientific, Inc., Agilent Technologies, Catalent Pharma Solutions, Sigma Aldrich, and Bio-Rad. 

• These participants are involved in collaborations with bioinformatics research firms in order to develop novel in-silico algorithms for computational estimation of toxicity of pharmaceutical and chemical products. 

• Moreover, these market entities are also focusing on entering untapped regions in order to maintain their share in market revenue. 

Request for free sample of "In-vitro Toxicology Testing Market Analysis Report" 

Home Infusion Therapy Market is Expected to Reach USD 28.3 Billion by 2024

The global home infusion therapy market is expected to reach USD 28.3 billion by 2024, according to a new report by Grand View Research, Inc. The rising significance of cost-containment in home infusion in comparison with in-patient settings is a high-impact rendering driver of the home infusion therapy market. Moreover, long-term cost savings in the treatment of chronic diseases associated with the home infusion therapy is primarily driving the growth of the industry during the forecast period.

As per a study published in NCBI in 2011, a cost containment program targets cost reduction and study associated patient’s preference pattern changes towards home infusion therapy. As per this study, a short-term reduction of over USD 2,247 in costs was achieved and a reduction of long-term costs of over USD 10,424 too, illustrating that significant cost reductions can be achieved through the incorporation of home infusion therapy.

Moreover, the rising penetration rate of home and alternate site services as a consequence of high patient preference due to the high awareness & recognition of benefits associated with the aforementioned are presumed to propel the growth of home infusion therapy market over the forecast period. 

The rising number of product innovations and initiatives to improve the safety associated with home infusion therapy is anticipated to bolster the demand for home infusion therapy devices market. For instance, infusion pump connectivity plays a key role when used within home settings, which include remote programming and wireless capability in infusion pumps that reduces the overall costs and ensures the safety of the infusion process as this enables to the healthcare professionals to monitor the patient in home settings remotely.

North America home infusion therapy market share, by product, 2014 - 2024 (USD Million)

View summary of "Home Infusion Therapy Market Analysis Report"  

Further key findings from the study suggest:

• On the basis of application, the anti-infective segment held a substantial share of the home infusion therapy market in terms of revenue of over 27.0% in 2015. Home-based infusion of anti-infective is increasingly preferred by patients suffering from chronic infections that cannot be properly treated through oral agents due to low absorption through GI tract. Within anti-infective, the IV push method is gaining popularity and is expected to experience growth in near future

• Needleless connectors are expected to witness a lucrative CAGR of over 9.0% over during the forecast period. This can be attributed to the rising demand for the safety of healthcare professionals as a result of the increasing number of cases of needle injuries, thus bolstering the growth for needleless connectors throughout the forecast period.

• Incorporation of Needlestick Safety and Prevention Act obligated Occupational Safety and Health Administration (OSHA) to elevate the standards, is expected to further accentuate the safety parameters thereby expected to boost the demand for needleless connectors over the forecast period

• North America dominated the regional market for home infusion therapy in 2015with a share of over 45.0% as a consequence of the presence of large geriatric population base with low mobility profile. The presence of supportive healthcare infrastructure, greater insurance coverage, and favorable reimbursement policies laid out by regulatory bodies are also inducing significant contributions towards industry growth in future.

• Asia Pacific is anticipated to emerge as a high growth market at a CAGR of over 10.5% overthe forecast period. The presence of large unmet needs in the emerging economies of Asia Pacific and growing initiatives over this region is impelling the growth for home infusion therapy. For instance, introduction of private healthcare establishments and nursing facilities with the advent of 12th Five Year Plan (2011-2015) in China. In addition, the increasing number of joint ventures between the U.S. health investors and Chinese senior care companies is expected to present the region with potential growth opportunities.

• Key players of home infusion therapy market include B. Braun Melsungen AG, Fresenius Kabi AG, Baxter, CareFusion Corporation and Hospira, Inc. Mergers & acquisitions, as well as, strategic collaborations with home infusion healthcare providers are the two key significant sustainability strategies employed by these prominent market participants. For instance, in February 2015, CareFusion renewed certifications for four separate patient care devices interoperability standards associated with its Alaris system smart infusion platform.

Request for free sample of "Home Infusion Therapy Market Analysis Report" 

Ambulatory Services Market Will Witness Significant Growth Owing To Surging Demand Across Various Application

Global ambulatory services market is expected to reach USD 3,428.5 billion by 2022, according to a new report by Grand View Research Inc. The market is driven by increasing aging population, ease-in-access and flexible timings, government initiatives to integrate acute and primary healthcare, and growing treatment costs. 

Aging population and increasing life expectancy have transformed the healthcare needs to provide services for existing co-morbidities, disabilities, and frailties. For providing accessible services to patients, there is an increasing demand for outpatient services, which help in cutting down on the long wait times in hospitals. 

The healthcare budgetary pressure on the government is also expected to decrease by providing efficient outpatient/ambulatory services. For instance, January 2015 report released by Alberta (province in Western Canada) stated that increasing seniors in the population, which accounted to 16% used over 41% of the direct healthcare costs. 

Browse full research report on Global ambulatory services market: http://www.grandviewresearch.com/industry-analysis/baby-diapers-market

Further key findings from the report suggest: 

• Primary care offices dominated the market in 2014 owing to increasing demand for private care facilities by patients. In addition, funding agencies such as the NHS along with Primary Healthcare Properties (PHP) invested USD 1.4 billion for the transformation of primary care for General Practitioner (GP) buildings.
• Specialty surgery is expected to witness rapid rise in demand due to the technological advancements enabling ophthalmic, orthopedic, and other surgeries to take place in the Ambulatory Surgical Centers (ASCs).
• Moreover, increasing technological advancement has driven the preference for non-surgical and minimally invasive surgeries. For instance, in 2014, the American Society of Plastic Surgery reported that around 90% of the procedures were minimally invasive, while the remaining 10% were surgical procedures. The report listed that the top five cosmetic minimally-invasive procedures were chemical peels, IPL treatments, laser skin resurfacing, laser hair removal, Botox, Dysport, and soft tissue fillers
• North America was the largest regional market with revenue share estimated at over 40% owing to increasing population with chronic diseases and favorable reimbursement for ambulatory services in the U.S.
• In March 2015, Tenet Healthcare and United Surgical Partners International (USPI) combined their forces to extend their network of ambulatory care units. This collaboration offered 20 imaging centers and around 265 short-day surgical facilities with 50 health system partnerships and 4,000 physicians.
• Europe was the second largest market in 2014. Private health in Europe is increasing owing to demographical changes, rising healthcare spending, and the increasing support from the NHS. Furthermore, initiatives of integrating outpatient services with technology are expected to propel market growth during the forecast period. In March 2012, Warwickshire NHS Trust (UHCW) and University Hospitals Coventry received the NHS grant of USD 406,867 to treat a virtual form of ambulatory center.
• In Asia Pacific, the concept of ambulatory services is gaining momentum and increasing healthcare costs owing to chronic diseases, aging population, and increasing hospital readmission have initiated the expansion of outpatient centers
• Industry contributors are striving to change the traditional methods of performing surgeries and introducing nonsurgical methods enabling surgeons to perform procedures in an effective manner. The American Society of Plastic Surgeons (ASPS), revealed that the overall demand for cosmetic surgeries increased by 3%, whereas demand for surgical procedures increased by only 1% as against non-surgical procedures, which increased by 4%.
• In November 2015, Weill Cornell Medicine entered into an agreement with Top Spring Huaxia Medical Investment Co. Ltd. Top Spring will help Weill Cornell to develop a modern outpatient diagnostic clinic in China.
• Some key players of this market include AmSurg Corp., Surgery Partners, Symbion, IntergraMed America, Inc., Nueterra, Terveystalo Healthcare Oyj, Aspen Healthcare, and Medical Facilities Corporation 

Read detailed report or request for sample of this research report:
http://www.grandviewresearch.com/industry-analysis/baby-diapers-market/request

Grand View Research has segmented the global ambulatory services market on the basis of procedures, devices, and regions: 

Global Ambulatory Services Types Outlook (Revenue, USD Million, 2012 – 2022)

• Primary Care Offices
• Outpatient Departments
• Emergency Departments
• Surgical Specialty
• Ophthalmology
• Orthopedics
• Gastroenterology
• Spinal Injections
• Plastic Surgery
• Others
• Medical Specialty

Ambulatory Services Regional Outlook (Revenue, USD Million, 2012 – 2022)

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Rest of Europe
• Asia Pacific
• Japan
• China
• Rest of Asia Pacific
• Latin America
• Brazil
• Rest of Latin America
• MEA
• South Africa
• Rest of MEA 

Browse more reports of this category by Grand View  Research: http://www.grandviewresearch.com/industry/personal-care-and-cosmetics

About Grand View Research                                             

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc

Web: www.grandviewresearch.com

Erectile Dysfunction Drugs Market Worth $3.2 Billion By 2022

The global erectile dysfunction drugs market is expected to reach USD 3.2 billion by 2022 according to a new report by Grand View Research Inc. Rising adoption of sedentary lifestyle and increasing prevalence of conditions causing erectile dysfunction such as stress, hypertension, and related medications are the key factors expected to widen the target population base for this market. 

The increasing risk of sexually transmitted diseases, narrowing of insurance coverage for erectile dysfunction treatment, growing threat from counterfeit drugs, and presence of social stigma in developing countries are some factors limiting penetration rates.

North America erectile dysfunction drugs market, by product, 2012-2022, (USD Million)

Further key findings from the report suggest:

• Viagra accounted for over 47.0% of the total revenue in 2014. It is generally considered as the first line of treatment for erectile dysfunction. Brand loyalty and advantages associated with this drug such as high efficacy, and effectiveness are the major factors attributing for its large market share.
• Cialis (tadalafil) from Eli Lilly & Co. and Levitra (vardenafil) from Bayer AG are known to be the competitors for Viagra globally. Cialis (tadalafil) was approved in 2003 by the U.S. FDA, as a prescription drug in the U.S. Cialis is also known as “The Weekend Pill” owing to its 36-hour effectiveness.
• After the patent expiration of key drugs such as Cialis (tadalafil) in 2017 and Levitra (vardenafil) in 2018, other drugs such as Stendra/Spedra, Zydena (udenafil), and Vitaros (Alprostadil Cream) are expected to capture the market share during the forecasts period.
• North America constituted the largest share of approximately 55.0% in 2013 of the total erectile dysfunction market. Extension of patent exclusivity rights for Viagra (sildenafil citrate) in the U.S. till 2019 along with introduction of new erectile dysfunction drugs such as Zydena (udenafil) and Stendra/Spedra (avanafil) will be the major factors responsible for market growth during the forecasts period.
• Asia Pacific accounted for a revenue share of over 16.5% in 2012 owing to the presence of a lucrative market for generic drugs, untapped opportunities, and increasing awareness related to erectile dysfunction in this region
• Apricus Biosciences Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., Bayer AG, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., S.K. Chemicals Co. Ltd., and Vivus, Inc. are some major players of this market
• Extensive R&D carried out by companies and high unmet needs in developing economies are expected to boost industrial growth. Key manufacturers are targeting regions with unmet clinical needs by entering into agreement with local manufacturers and distributors. Key players are constantly engaged in developing novel drugs in an attempt to improve the presence and ensure sustainability. 

Grand View Research has segmented the global erectile dysfunction drugs market on the basis of product and region:

Erectile Dysfunction Drugs Product Outlook (Revenue, USD Million, 2012 – 2022)

• Viagra (sildenafil citrate)
• Cialis (tadalafil)
• Levitra/Staxyn (vardenafil)
• Stendra/Spedra (avanafil)
• Zydena (udenafil)
• Vitaros (Alprostadil Cream)
• Others

Erectile Dysfunction Drugs Regional Outlook (Revenue, USD Million, 2012 – 2022)

• North America
• Europe
• Asia Pacific
• RoW

Request for free sample of "Erectile Dysfunction Drugs Market"

Therapeutic Respiratory Device Market Analysis and Growth

Global therapeutic respiratory devices market is expected to reach USD 19.2 billion by 2022, according to a new report by Grand View Research Inc. Increasing geriatric population contributing towards growing target disease prevalence levels is a key factor expected to attribute towards market growth.

Prevalence of these disorders is expected to constantly rise over the next six years owing to the growing prevalence of cardiovascular disorders, hypertension, obesity, and other lifestyle induced disorders.

Increasing need of emergency treatment for prolonged illnesses and protracted treatment associated with lung diseases in children as well as adults are expected to drive market growth over the next seven years. The introduction of technology innovations is expected to serve as future growth opportunities.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/therapeutic-respiratory-devices-market

Further key findings from the study suggest:

• Positive airway pressure devices dominated the product segment in 2014, with market size valued at over 4.0 billion. Growing demand for portable PAP devices and high associated efficacy rates are some key factors expected to drive segment growth.
• HEPA filtration was the largest technology segment, accounting for over 35.0% of the market share in 2014. High usage of these filters in therapeutic respiratory devices is a major factor contributing towards the segment’s market position.
• Furthermore, technological advancements in these filters such as the availability of washable HEPA filters and incorporation of HEPA 4 technology is further likely to boost usage rates.
• Regionally, North America dominated the therapeutic respiratory devices market owing to the presence of high diagnosis rates supported by the presence of sophisticated healthcare infrastructure. Increasing government funding, and the availability of well structured reimbursement framework will also contribute towards healthy market growth.
• Asia Pacific is expected to witness significant gains, at over 12.0% during the forecast period, driven by the rising incidence of respiratory disorders in the region. Rising healthcare expenditure levels and the presence of high unmet medical need is also a vital growth driver.
• Key players operating in the therapeutic respiratory devices market include Smiths Medical, GE Healthcare, CareFusion Corporation, Philips Healthcare and Covidien Plc.
• The market is expected to remain highly competitive, which may see extensive R&D investments aimed at technology innovation, as a widely utilized business strategy.
• Grand View Research has segmented the global therapeutic respiratory devices market on the basis of products, technology, filters and region:

Product Outlook (Revenue, USD Million, 2012 – 2022)

• Nebulizers
• Compressor-based nebulizers
• Piston-based hand-held nebulizers
• Ultrasonic nebulizers
• Humidifiers
• Heated humidifiers
• Passover humidifiers
• Integrated humidifiers
• Built-in humidifiers
• Stand-alone humidifiers
• Oxygen concentrators
• Fixed oxygen concentrators
• Portable oxygen concentrators
• Positive airway pressure devices
• Continuous positive airway pressure devices
• Auto-titrating positive airway pressure devices
• Bi-level positive airway pressure devices
• Ventilators
• Adult ventilators
• Neonatal ventilators
• Gas Analyzers
• Capnographs

Technology Outlook (Revenue, USD Million, 2012 – 2022)

• Electrostatic filtration
• HEPA filter technology
• Hollow fiber filtration
• 
  

Filters Outlook (Revenue, USD Million, 2012 – 2022)

•  Nebulizer filters
• Inlet filters
• Replacement filters
• Cabinet filters
• Humidifier filters
• Wick filters
• Permanent cleanable filters
• Mineral absorption pads
• Demineralization cartridges
• Positive airway pressure device filters
• Ultra fine foam inlet filters
• Polyester non-woven fiber filters
• Acrylic & polypropylene fiber filters
• Oxygen concentrators filters
• HEPA filters
• Cabinet filters
• Pre-inlet filters
• Inlet filters
• Micro disk filters
• Felt intake filters
• Bacterial filters
• Hollow membrane filters
• Ventilator filters
• Mechanical filters
• HEPA filters
• ULPA filters
• Activated carbon filters
• Electrostatic filters
• Tribocharged filters
• Fibrillated filters

·     Regional Outlook (Revenue, USD Million, 2012 – 2022)

• North America
• U.S.
• Canada
• Europe
• Spain      
• Germany
• France
•  Italy
• Switzerland
• Asia Pacific
• India
• Japan
• China
• Latin America
• Brazil
• Mexico
• Middle East and Africa (MEA)
• South Africa

Request for free sample of this report @ http://www.grandviewresearch.com/industry-analysis/therapeutic-respiratory-devices-market/request

About Grand View Research

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.

Contact:

Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States

Phone:  1-415-349-0058

Toll Free:  1-888-202-9519

Email:  sales@grandviewresearch.com

Website: Grand View Research

Blood Gas And Electrolyte Analyzers Market Growth

Global Blood Gas And Electrolyte Market is expected to reach USD 653.5 million by 2022, according to a new study by Grand View Research Inc. Rising number of patients in ICU and critical care units and increasing demand for high throughput and integrated systems are some key factors likely to drive the blood gas and electrolyte analyzers market. Growing global geriatric population base is also expected to significantly contribute towards market growth over the forecast period, by triggering the incidence rates of target diseases and widening the base of patients requiring critical care. 

The availability of blood gas analyzers has helped enhance the care of critically ill patients allowing for frequent diagnosis and monitoring of respiratory problems and ability to guide prognosis and therapy. Rising demand for technically advanced sleek handheld devices involving short turnaround time has resulted in the development of more compact, sleek, handheld point-of-care devices.

For instance, the OPTI CCA-TS2 blood gas and electrolyte analyzers use innovative optical technology and provide fast results while requiring minimal maintenance.

Global blood gas and electrolyte analyzers market, by product, 2012-2022 (USD Million)

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/blood-gas-and-electrolyte-analyzers

Further key findings from the study suggest:

Portable analyzers dominated the market with a share of over 60.0% in 2014 and are also expected to witness lucrative growth over the forecast period. Growing demand for automated, self-monitoring, portable devices, shorter analysis time, and quick accurate results are key factors boosting the growth of this segment.

Rising need for analyzers, which can analyze blood and electrolyte samples together are swiftly gaining popularity among users.

North America accounted for more than 40% of the blood gas and electrolyte analyzers market in 2014. 

Presence of high unmet needs clubbed with rapidly improving healthcare infrastructure in the emerging markets of India and China is expected to help Asia Pacific grow at a lucrative rate throughout the forecast period. Growing demand for decentralized point-of-care diagnostic facilities handling large volumes of diagnostic tests is also expected to drive regional market growth.

For the purpose of this study, Grand View Research has segmented the blood gas and electrolyte analyzers market on the basis of products, application, end-use, and region:

Global Blood Gas and Electrolyte Analyzers Market, Product Outlook (Revenue, USD Million, 2012 – 2022)

·        Benchtop

·        Portable

Global Blood Gas and Electrolyte Analyzers Market, Application Outlook (Revenue, USD Million, 2012 – 2022)

·        Blood gas analyzers

·        Electrolyte analyzers

·        Combined analyzers

Global Blood Gas and Electrolyte Analyzers Market, End-use Outlook (Revenue, USD Million, 2012 – 2022)

·        Clinical laboratories

·        Point-of-care

Blood Gas and Electrolyte Analyzers Market, Regional Outlook (Revenue, USD Million, 2012 – 2022)

·        North America

·        U.S.

·        Canada

·        Europe

·        Germany

·        France

·        Spain

·        Asia Pacific

·        Japan

·        China

·        Latin America

·        Brazil

·        Mexico

·        Middle East and Africa (MEA)

·        South Africa

Request for free sample of this report @ http://www.grandviewresearch.com/industry-analysis/blood-gas-and-electrolyte-analyzers/request

About Grand View Research

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights.

Contact:

Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States

Phone:  1-415-349-0058

Toll Free:  1-888-202-9519

Email:  sales@grandviewresearch.com

Website: Grand View Research